Synergistic antileukemic activity of carnosic acid-rich rosemary extract and the 19-nor Gemini vitamin D analogue in a mouse model of systemic acute myeloid leukemia

Oncology

Volumn 75, Issue 3-4, 2008, Pages 203-214

  Shabtay, Ayelet ^a   Sharabani, Hagar ^a   Barvish, Zeev ^a   Kafka, Michael ^b   Amichay, Doron ^b   Levy, Joseph ^a   Sharoni, Yoav ^a   Uskokovic, Milan R ^c   Studzinski, George P ^d   Danilenko, Michael ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c Bioxell Inc   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Acute myeloid leukemia; Carnosic acid; Differentiation; Hypercalcemia; Rosemary extract; Syngeneic mouse model; Vitamin D

Indexed keywords

1,25 DIHYDROXY 21 (3 HYDROXY 3 METHYL BUTYL) 19 NOR CHOLECALCIFEROL; CARNOSIC ACID; GLUTATHIONE; REACTIVE OXYGEN METABOLITE; RO 27 2310; RO 272310; RO 275646; ROSMARINUS OFFICINALIS EXTRACT; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; FEMALE; LEUKEMIA CELL; LEUKOCYTE COUNT; MOUSE; MYELOMONOCYTIC LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIOXIDANTS; BONE MARROW; CALCITRIOL; CELL DIFFERENTIATION; CELL PROLIFERATION; CHOLECALCIFEROL; DISEASE MODELS, ANIMAL; DITERPENES, ABIETANE; DRUG SYNERGISM; HUMANS; IMMUNOBLOTTING; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED BALB C; PLANT EXTRACTS; REACTIVE OXYGEN SPECIES; ROSMARINUS; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 53549116450     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000163849     Document Type: Article

References (50)

1. Estey E, Dohner H: Acute myeloid leukaemia. Lancet 2006;368:1894-1907.
2. Eelen G, Gysemans C, Verlinden L, Vanoirbeek E, De Clercq P, Van Haver D, Mathieu C, Bouillon R, Verstuyf A: Mechanism and potential of the growth-inhibitory actions of vitamin D and analogs. Curr Med Chem 2007;14:1893-1910.
3. Deeb KK, Trump DL, Johnson CS: Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007;7:684-700.
4. Trump DL, Muindi J, Fakih M, Yu WD, Johnson CS: Vitamin D compounds: clinical development as cancer therapy and prevention agents. Anticancer Res 2006;26:2551-2556.
5. 3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells. Cancer Res 1999;59:4023-4029.
6. Alagbala AA, Johnson CS, Trump DL, Posner GH, Foster BA: Antitumor effects of two less-calcemic vitamin D analogs (paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells. Oncology 2006;70:483-492.
7. Zhang J, Posner GH, Danilenko M, Studzinski GP: Differentiation-inducing potency of the seco-steroid JK-1624F2-2 can be increased by combination with an antioxidant and a p38MAPK inhibitor which upregulates the JNK pathway. J Steroid Biochem Mol Biol 2007;105:140-149.
8. Maehr H, Uskokovic M, Adorini L, Penna G, Mariani R, Panina P, Passini N, Bono E, Perego S, Biffi M, Holick M, Spina C, Suh N: Calcitriol derivatives with two different side chains at C-20. III. An epimeric pair of the Gemini family with unprecedented antiproliferative effects on tumor cells and renin mRNA expression inhibition. J Steroid Biochem Mol Biol 2007;103:277-281.
9. 3-resistant variant can be sensitized by TPA. J Steroid Biochem Mol Biol 2003;84:199-209.
10. 3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol 2005;241:49-61.
11. 2(a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Cancer Res 2005;65:2488-2497.
12. 2-induced cytotoxicity while inhibiting caspase activation. J Steroid Biochem Mol Biol 2006;101:151-160.
13. 3 as an immune therapy in animals bearing squamous cell carcinomas. Otolaryngol Head Neck Surg 2005;133:611-618.
14. 3 derivatives and rosemary preparations in a mouse model of myeloid leukemia. Int J Cancer 2006;118:3012-3021.
15. Flaig TW, Barqawi A, Miller G, Kane M, Zeng C, Crawford ED, Glode LM: A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer 2006;107:266-274.
16. 3) and dexamethasone in androgen-independent prostate cancer. Cancer 2006;106:2136-2142.
17. Yamada K, Mizusawa M, Harima A, Kajiwara K, Hamaki T, Hoshi K, Kozai Y, Kodo H: Induction of remission of relapsed acute myeloid leukemia after unrelated donor cord blood transplantation by concomitant low-dose cytarabine and calcitriol in adults. Eur J Haematol 2006;77:345-348.
18. 3. Oncol Res 1997;9:31-39.
19. Kang SN, Lee MH, Kim KM, Cho D, Kim TS: Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by silibinin: involvement of protein kinase C. Biochem Pharmacol 2001;61:1487-1495.
20. 3 in induction of leukemia HL60 cell differentiation through the JNK/AP-1/Egr-1 pathway. J Cell Physiol 2005;204:964-974.
21. 3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium. Cancer Res 2003;63:1325-1332.
22. Danilenko M, Wang X, Studzinski GP: Carnosic acid and promotion of monocytic differentiation of HL60-G cells initiated by other agents. J Natl Cancer Inst 2001;93:1224-1233.
23. 3 and retinoic acid. Nutr Cancer 2001;41:135-144.
24. 3 analogues with two side chains. J Cell Biochem Suppl 2001;(suppl 36):179-190.
25. 3 analogues: disassociation of their prominent antileukemic effects from their lack of calcium modulation. Cancer Res 2001;61:3361-3368.
26. Hosmer DW, Lemeshow S: Applied Survival Analysis: Regression Modeling of Time to Event Data. New York, Wiley, 1999.
27. Moreno S, Scheyer T, Romano CS, Vojnov AA: Antioxidant and antimicrobial activities of rosemary extracts linked to their polyphenol composition. Free Radic Res 2006;40:223-231.
28. Chen C, Kong AN: Dietary cancer-chemopreventive compounds: from signaling and gene expression to pharmacological effects. Trends Pharmacol Sci 2005;26:318-326.
29. Berdel WE, Okamoto S, Danhauser-Riedl S, Hong CI, Winton EF, West CR, Rastetter J, Vogler WR: Therapeutic activity of 1-β-D- arabinofuranosylcytosine conjugates of lipids in WEHI-3B leukemia in mice. Exp Hematol 1989;17:364-367.
30. Kogan SC, Ward JM, Anver MR, Berman JJ, Brayton C, Cardiff RD, Carter JS, de Coronado S, Downing JR, Fredrickson TN, Haines DC, Harris AW, Harris NL, Hiai H, Jaffe ES, MacLennan IC, Pandolfi PP, Pattengale PK, Perkins AS, Simpson RM, Tuttle MS, Wong JF, Morse HC 3rd: Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 2002;100:238-245.
31. 3 and its analogs. Exp Cell Res 2004;298:339-358.
32. Gius D, Botero A, Shah S, Curry HA: Intracellular oxidation/reduction status in the regulation of transcription factors NF-κB and AP-1. Toxicol Lett 1999;106:93-106.
33. Giles GI: The redox regulation of thiol dependent signaling pathways in cancer. Curr Pharm Des 2006;12:4427-4443.
34. Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, Aggarwal BB: Resveratrol blocks interleukin-1β-induced activation of the nuclear transcription factor NF-κB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 2003;102:987-995.
35. Tamatani T, Azuma M, Motegi K, Takamaru N, Kawashima Y, Bando T: Cepharanthin-enhanced radiosensitivity through the inhibition of radiation-induced nuclear factor-kappaB activity in human oral squamous cell carcinoma cells. Int J Oncol 2007;31:761-768.
36. 3. Cancer Res 2006;66:4402-4409.
37. 3-induced growth inhibition. J Biol Chem 2002;277:25884-25892.
38. 3 by induction of the vitamin D receptor. J Biol Chem 2001;276:3727-3732.
39. Sekiya M, Adachi M, Hinoda Y, Imai K, Yachi A: Downregulation of Wilms' tumor gene (wt1) during myelomonocytic differentiation in HL60 cells. Blood 1994;83:1876-1882.
40. Anuchapreeda S, Limtrakul P, Thanarattanakorn P, Sittipreechacharn S, Chanarat P: Inhibitory effect of curcumin on WT1 gene expression in patient leukemic cells. Arch Pharm Res 2006;29:80-87.
41. Singletary K, MacDonald C, Wallig M: Inhibition by rosemary and carnosol of 7,12-dim ethylbenz(a)anthracene (DMBA)-induced rat mammary tumorigenesis and in vivo DMBA-DNA adduct formation. Cancer Lett 1996;104:43-48.
42. Singh RP, Deep G, Chittezhath M, Kaur M, Dwyer-Nield LD, Malkinson AM, Agarwal R: Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst 2006;98:846-855.
43. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK: Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 2007;13:3423-3430.
44. Agoston ES, Hatcher MA, Kensler TW, Posner GH: Vitamin D analogs as anti-carcinogenic agents. Anticancer Agents Med Chem 2006;6:53-71.
45. Lambert JD, Hong J, Yang GY, Liao J, Yang CS: Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am J Clin Nutr 2005;81:284S-291S.
46. Hoepfl J, Miething C, Grundler R, Gotze KS, Peschel C, Duyster J: Effects of imatinib on bone marrow engraftment in syngeneic mice. Leukemia 2002;16:1584-1588.
47. Williams RT, Roussel MF, Sherr CJ: Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2006;103:6688-6693.
48. 3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci USA 1983;80:201-204.
49. 3 analogues and other differentiation inducers in combination with antileukemic drugs: in vitro and in vivo studies. Cancer Res 1987;47:567-572.
50. 3 prolongs survival time of leukemic mice. Proc Natl Acad Sci USA 1990;87:3929-3932.